FirstWord

Construction on the 225,000-square-foot facility is expected to start this year.

Lisraya (brepocitinib) was approved based on the results of the Phase III VALOR trial.

GB-0895 suppressed key inflammatory biomarkers for at least six months in certain asthma patients, according to data made public ahead of the European Respiratory Society Congress.

The funding will support an AI-driven search for new proteins linked to the pregnancy complications.

The proposed offering comes a week after Phase III melanoma data for its Merck & Co.-partnered asset sent shares soaring.

Cytokinetics' non-obstructive HCM win, Redemplo's role in sHTG, and post-mortems from CARDIO-TTransform and Librexia ACS are among the trial readouts FirstWord is tracking at this year's ESC meeting in Munich.

FAIRFAX, VA, UNITED STATES, August 27, 2026 /EINPresswire.com/ -- New Phase 3 clinical trial findings spanning the diagnosis, imaging, and treatment of cardiac amyloidosis will be presented at the Ame...

Key takeaways The impact of taking blood pressure-lowering medicines as prescribed was studied in an analysis of nine trials.Cardiovascular events were reduced only in patients with high medication ad...

Phase 1/2 dosing completed across all dose cohorts; participant evaluations ongoingPreliminary safety observations show ECUR-506 was generally well tolerated, with no unexpected treatment-related safe...

BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the...